Loading…
Pulmonx Corporation is projected to rise to $2.09 by 2027, a +36% move from its current price of $1.54. LUNG is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/12/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 14 | $1.47 | $1.54 | $1.61 | +0.02% |
| Jul 15 | $1.45 | $1.54 | $1.64 | +0.04% |
| Jul 16 | $1.43 | $1.54 | $1.66 | +0.06% |
| Jul 17 | $1.41 | $1.54 | $1.68 | +0.08% |
| Jul 18 | $1.40 | $1.54 | $1.70 | +0.10% |
| Jul 19 | $1.38 | $1.54 | $1.72 | +0.12% |
| Jul 20 | $1.37 | $1.54 | $1.73 | +0.14% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $1.37 | $1.54 | $1.73 | +0.14% |
| Week 2 | $1.31 | $1.54 | $1.82 | +0.28% |
| Week 3 | $1.26 | $1.55 | $1.90 | +0.43% |
| Week 4 | $1.22 | $1.55 | $1.96 | +0.57% |
| Week 5 | $1.19 | $1.55 | $2.02 | +0.71% |
| Week 6 | $1.16 | $1.55 | $2.07 | +0.86% |
| Week 7 | $1.14 | $1.56 | $2.12 | +1.00% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Pulmonx Corporation is a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease. It offers Zephyr Endobronchial Valve; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation.
The company also offers LungTraX Platform, a cloud-based quantitative computed tomography analysis service that provides physicians with multiple products, such as LungTraX Connect to improve workup efficiency; LungTraX Detect to enable patient identification; and StratX Lung report that is designed for solution that includes information on emphysema destruction, fissure completeness, and lobar volume to help identify target lobes for treatment with Zephyr Valves.
It serves emphysema patients in the United States, Europe, the Middle East, Africa, the Asia Pacific, and internationally. The company was formerly known as Pulmonx and changed its name to Pulmonx Corporation in December 2013. Pulmonx Corporation was incorporated in 1995 and is headquartered in Redwood City, California.
Pulmonx Corporation (LUNG) is currently priced at $1.47 with a market capitalization of $62.09M and a rank of 4491. This places it among smaller-cap healthcare equities with a focused device portfolio for emphysema treatment.
The 2026 forecast presents an average price of $1.47 with neutral sentiment, within a 30-day range of $1.08 to $2.00. From 2027 onward, the outlook improves, with the average forecast rising toward higher levels and positive ROI trajectories.
By 2027 the average is projected at $2.00 with a 36.4% ROI and bullish sentiment; by 2040 the average is $4.16 with an 182.7% ROI; and by 2050 the average is $7.39 with a 402.4% ROI, signaling a strong long-term upside if assumptions hold.
A major floor 31.2% below — a decisive break under it would weaken the trend.
The nearest floor, 18.8% below — buyers have tended to step in here.
The nearest ceiling, 9.1% above — a clean break opens room to run.
A major ceiling 31.2% above — clearing it would confirm fresh momentum.
Key LUNG support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of LUNG market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $1.49 | Buy | $1.48 | Buy |
| MA 10 | $1.42 | Buy | $1.44 | Buy |
| MA 20 | $1.36 | Buy | $1.42 | Buy |
| MA 50 | $1.40 | Buy | $1.42 | Buy |
| MA 100 | $1.43 | Buy | $1.49 | Buy |
| MA 200 | $1.64 | Sell | $1.88 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 58.07 | Neutral |
| Stoch RSI (14) | 97.88 | Sell |
| CCI (20) | 133.71 | Buy |
| Williams %R (14) | 0.00 | Info |
| MACD (12,26,9) | 0.02 | Buy |
| ROC (12) | 20.31 | Buy |
| Bollinger %B (20,2) | 0.95 | Neutral |
| Stochastic %K (14) | 100.00 | Sell |
| TRIX (15) | -0.08 | Sell |
| Awesome (5,34) | 0.05 | Buy |
| Ultimate (7,14,28) | 65.73 | Neutral |
| Momentum (10) | 0.29 | Buy |
| Aroon Osc (25) | -60.00 | Sell |
| Hull MA (9) | 1.52 | Buy |
| ADX (14) | 13.89 | Neutral |
| ATR (14) | 0.06 | Info |
The near-term technical picture shows bullish momentum embedded in the data. RSI14 is 60, indicating positive trend strength.
Key moving averages place the near-term baseline just above the current price, with SMA50 at $1.38 and SMA200 at $1.64. Immediate support sits at $1.25, while resistance is at $1.68. The 30-day price range spans from $1.08 to $2.00, illustrating room for movement in either direction.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $1.17 | $1.54 | $2.12 | 0% | Neutral | |
| $1.57 | $2.09 | $3.00 | +36% | Bullish | |
| $1.40 | $1.96 | $2.97 | +27% | Bullish | |
| $1.43 | $2.08 | $3.30 | +35% | Bullish | |
| $1.37 | $2.07 | $3.40 | +35% | Bullish | |
| $1.27 | $1.99 | $3.36 | +29% | Bullish | |
| $1.41 | $2.28 | $3.97 | +48% | Bullish | |
| $1.59 | $2.65 | $4.71 | +72% | Bullish | |
| $1.85 | $3.19 | $5.80 | +107% | Bullish | |
| $1.97 | $3.49 | $6.48 | +127% | Bullish | |
| $2.21 | $4.48 | $9.05 | +191% | Bullish | |
| $3.51 | $7.81 | $17.81 | +407% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $1.17 | $1.54 | $1.82 | +0.00% |
| August 2026 | $1.24 | $1.49 | $1.85 | -3.35% |
| September 2026 | $1.29 | $1.57 | $1.99 | +5.39% |
| October 2026 | $1.29 | $1.58 | $2.03 | +0.72% |
| November 2026 | $1.25 | $1.54 | $2.00 | -2.51% |
| December 2026 | $1.30 | $1.62 | $2.12 | +4.85% |
Click any year to see its month-by-month LUNG forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
By 2026, LUNG could reach as high as $2.12, with a base case around $1.54 and support toward $1.17 — roughly 0% from $1.54. A consolidation phase looks the most probable path here.
Expect LUNG to range from $1.57 to $3.00 through 2027. The $2.09 average target implies a +36% move from current prices. That is up +36% on the projected 2026 average. Momentum favours further upside here.
The LUNG price prediction for 2028 points to an average of $1.96 (low $1.40, high $2.97) — a potential gain of +27% on today's $1.54. Buyers look set to stay in control over this stretch.
In 2029, LUNG is projected to trade between $1.43 and $3.30, averaging $2.08 — a potential gain of +35% from today's $1.54. That is up +6% on the projected 2028 average. Momentum favours further upside here.
Pulmonx Corporation's 2030 outlook centres on $2.07, within a $1.37 to $3.40 range. That is -1% versus the projected 2029 average. That marks a +35% change versus current levels. Buyers look set to stay in control over this stretch.
By 2031, LUNG could reach as high as $3.36, with a base case around $1.99 and support toward $1.27 — roughly +29% from $1.54. Momentum favours further upside here.
Expect LUNG to range from $1.41 to $3.97 through 2032. The $2.28 average target implies a +48% move from current prices. That is up +15% on the projected 2031 average. Buyers look set to stay in control over this stretch.
The LUNG price prediction for 2033 points to an average of $2.65 (low $1.59, high $4.71) — a potential gain of +72% on today's $1.54. Momentum favours further upside here.
In 2034, LUNG is projected to trade between $1.85 and $5.80, averaging $3.19 — a potential gain of +107% from today's $1.54. That is up +20% on the projected 2033 average. Buyers look set to stay in control over this stretch.
Pulmonx Corporation's 2035 outlook centres on $3.49, within a $1.97 to $6.48 range. That is up +10% on the projected 2034 average. That marks a +127% change versus current levels. Momentum favours further upside here.
By 2040, LUNG could reach as high as $9.05, with a base case around $4.48 and support toward $2.21 — roughly +191% from $1.54. Buyers look set to stay in control over this stretch.
Expect LUNG to range from $3.51 to $17.81 through 2050. The $7.81 average target implies a +407% move from current prices. That is up +74% on the projected 2040 average. Momentum favours further upside here.
Investing $1,000 in LUNG today (≈ 649.350649 LUNG) could be worth
$5,071.98
+$4,071.98 (+407%) by 2050 · US Dollar
Based on the average projected LUNG price of $7.81 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in LUNGwould be worth at today's price.
$1,000 invested in LUNG on Jul 10, 2025 (≈ 377.358477 LUNG) would be worth
$581.13
-$418.87 (-41.9%) today · 0.58× · US Dollar
Based on a LUNG entry price of $2.65 vs. today's $1.54.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $1.39 | $1,107.91 | +10.8% |
| 1 month ago | $1.43 | $1,076.92 | +7.7% |
| 3 months ago | $1.37 | $1,124.09 | +12.4% |
| 6 months ago | $1.99 | $773.87 | -22.6% |
| 1 year ago | $2.65 | $581.13 | -41.9% |
| All time (5.0y) ago | $39.45 | $39.04 | -96.1% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our LUNG forecast.
Our base-case forecast reaches $3.10 around 2034.
Implied market cap at $3.10: $130.94M
The multi-year forecast paints a bullish trajectory with meaningful upside in later years. In 2030, the average price is $1.96 with a 33.3% ROI and bullish sentiment.
In 2040, the average price is $4.16 with a 182.7% ROI and bullish sentiment, suggesting substantial appreciation if the forecast materializes.
In 2050, the average price is $7.39 with a 402.4% ROI and bullish sentiment, reflecting a pronounced long-term upside. These figures are estimates and not guarantees, reflecting potential outcomes under the given assumptions and market conditions.
Tap a question to reveal the answer.
The forecast shows an average price of $1.96 in 2030 with a 33.3% ROI and bullish sentiment.
Forecasts indicate a bullish path after 2026, with 2027 average $2.00 and ROI 36.4%, 2040 average $4.16 with ROI 182.7%, and 2050 average $7.39 with ROI 402.4%, though these are estimates and not guarantees.
Yes, the forecast shows higher potential on the upside, with maximums including $5.56 in 2034, $6.35 in 2035, $8.58 in 2040, and $16.99 in 2050.
Current price is $1.47 and market cap is $62.09M.
RSI14 is 60 with bullish sentiment. The SMA50 is $1.38 and the SMA200 is $1.64, with support at $1.25 and resistance at $1.68; the 30-day range is $1.08–$2.00.
Pulmonx Corporation Community Discussion
0Share your Pulmonx Corporation price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.